MEDITRUST HEALTH, SINO BIOPHARM INK PACT TO ADVANCE DRUG-INSURANCE INTEGRATION

During the 8th China International Import Expo (CIE), Sino Biopharmaceutical Limited (“Sino Biopharm”) and Shanghai MediTrust Health Technology Group Co., Ltd. (“MediTrust Health”) signed a strategic cooperation agreement.

- TBG NETWORK

The two parties will carry out in-depth cooperation around innovative drugs and commercial insurance, jointly explore a new model of drug-insurance integration, and help more patients access high-quality, affordable medicines at an earlier stage.Mr. Tse Hsin, Executive Director and Senior Vice President of Sino Biopharm, and Mr. Wang Rundong, President of MediTrust Health, attended the signing ceremony and delivered speeches. Mr. Li Zhigang, Chairman of MediTrust Health, was present as a witness.Mr. Tse Hsin highlighted that as a leading Chinese innovative pharmaceutical group, Sino Biopharm generates annual revenue of approximately RMB 30 billion, ranks 38th among the Top 50 Global Pharmaceutical Companies, and has a pipeline of over 120 innovative drugs. With evolving demographics and deepening healthcare reforms, commercial health insurance has become a critical channel for innovative drugs to reach the market. This not only eases pressure on public medical insurance funds but also fuels R&D investment, fostering a sustainable industry cycle.He emphasized MediTrust Health's role as a pivotal platform connecting pharmaceutical companies, insurers,